SCHEMBL979019

SCHEMBL979019

COc1ccc(-c2ccc3cc(CO)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 10/20 0.67
RARG P13631 10/20 0.67
RARA P10276 7/20 0.67
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
NR1I2 O75469 1/20 0.67
LMNA P02545 1/20 0.67
PGR P06401 1/20 0.67
HSPD1 P10809 1/20 0.67
GOT1 P17174 1/20 0.67
GLRA1 P23415 1/20 0.67
BLM P54132 1/20 0.67
HSPE1 P61604 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
HDAC11 Q96DB2 4/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29462719 1.00 RARB (0.67) RARBRARGRARAMEN1KMT2A
SCHEMBL5828464 0.88 RARB (0.64) RARBRARGRARAMEN1KMT2A
SCHEMBL21746062 0.88 RARB (0.64) RARBRARGRARAMEN1KMT2A
SCHEMBL3318535 0.87 S1PR1 (0.53) RARBRARGRARAMEN1KMT2A
SCHEMBL25253159 0.85 RARB (0.64) RARBRARGRARAMEN1KMT2A
SCHEMBL30510654 0.85 RARB (0.64) RARBRARGRARAMEN1KMT2A
SCHEMBL1196174 0.84 RARB (0.71) RARBRARGRARAMEN1KMT2A
SCHEMBL26688920 0.84 RARB (0.64) RARBRARGRARAMEN1KMT2A
SCHEMBL5827886 0.84 RARB (0.70) RARBRARGRARAMEN1KMT2A
Adapalene SCHEMBL21724948 0.83 RARB (0.83) RARBRARGRARAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150098918-A1 CREAM GELS COMPRISING AT LEAST ONE RETINOID AND BENZOYL PEROXIDE GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-04-09 US claimed
US-20100166852-A1 Cream gels comprising at least one retinoid and benzoyl peroxide GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-07-01 US claimed
US-20090318550-A1 Emulsions comprising at least one retinoid and benzoyl peroxide GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-12-24 US claimed
US-RE34805-E Treatment of dermatologic diseases, degeneration of conjunctive tissues; antitumor activity CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) 1994-12-06 US claimed
US-4940696-A Benzonaphthalene derivatives and their use in therapeutic and cosmetic compositions CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES (CIRD) (FR) 1990-07-10 US claimed
EP-0199636-B1 BENZONAPHTHALENIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN PHARMACY AND COSMETICS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. Groupement d'Intérêt Economique dit: (FR) 1989-02-08 EP claimed
EP-0199636-A1 Benzonaphthalenic derivatives, process for their preparation and their use in pharmacy and cosmetics CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. Groupement d'Intérêt Economique dit: (FR) 1986-10-29 EP claimed
US-12195424-B2 Antibiotic compounds THE GENERAL HOSPITAL CORPORATION (US) 2025-01-14 US disclosed
US-20230346727-A1 COMPOUNDS FOR THE TREATMENT OF HEMOPHILIA UNIVERSITE GRENOBLE ALPES (FR) 2023-11-02 US disclosed
US-20230346727-A1 COMPOUNDS FOR THE TREATMENT OF HEMOPHILIA UNIVERSITE GRENOBLE ALPES (FR) 2023-11-02 US disclosed
US-20230346727-A1 COMPOUNDS FOR THE TREATMENT OF HEMOPHILIA UNIVERSITE GRENOBLE ALPES (FR) 2023-11-02 US disclosed
CN-116710080-A Compounds for treatment of hemophilia 格勒诺布尔大学 2023-09-05 CN disclosed
EP-4185281-A1 COMPOUNDS FOR THE TREATMENT OF HAEMOPHILIA Université Grenoble Alpes (FR) 2023-05-31 EP disclosed
US-5212303-A Benzonaphthalene derivatives, a process for their preparation and their use in therapeutic and cosmetic compositions CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) 1993-05-18 US disclosed
US-5183889-A For topical or systemic treatment of dermatologic disease, degeneration of conjunction tissues and tumors CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) 1993-02-02 US disclosed
US-5098895-A Skin disorders and antitumor agents CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) 1992-03-24 US disclosed
US-4940696-A Benzonaphthalene derivatives and their use in therapeutic and cosmetic compositions CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES (CIRD) (FR) 1990-07-10 US disclosed
EP-0199636-B1 BENZONAPHTHALENIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN PHARMACY AND COSMETICS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. Groupement d'Intérêt Economique dit: (FR) 1989-02-08 EP disclosed
US-4717720-A DERMATOLOGIC DISEASES, CONJUCTIVE TISSUE DEGENERATION AND ANTI-TUMOR ACTIVITY CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) 1988-01-05 US disclosed
EP-0199636-A1 Benzonaphthalenic derivatives, process for their preparation and their use in pharmacy and cosmetics CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. Groupement d'Intérêt Economique dit: (FR) 1986-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346727-A1 COMPOUNDS FOR THE TREATMENT OF HEMOPHILIA PROC, F2, F8 RARB 1848/4885RARG 1713/4885RARA 1675/4885
US-12195424-B2 Antibiotic compounds CUTA, NRDC, CLPP RARB 26/4885RARG 78/4885RARA 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.